GERN Geron Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: GERN

Price (delayed)

$1.505

Market cap

$966.92M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.11

Enterprise value

$1.15B

?
Relative Growth: Rel. Growth: 64
Relative Strength: Rel. Strength: 75
Relative Valuation: Rel. Valuation: 12
Relative Profitability: Rel. Profitability: 40

Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO ® (imetelstat) is approved in the United States ...

Highlights
The revenue has grown by 24% YoY and by 4.3% from the previous quarter
The net income has grown by 23% YoY
The quick ratio has contracted by 24% YoY but it has grown by 4.1% from the previous quarter
Geron's equity has decreased by 16% YoY and by 4.6% from the previous quarter
The gross margin has contracted by 4.4% YoY and by 3.9% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.geron.com
Peers: GILD TECH INCY STEM

Key stats

What are the main financial stats of GERN

GERN stock price

How has the Geron stock price performed over time
Intraday
-5.35%
1 week
-1.63%
1 month
17.58%
1 year
7.5%
YTD
14.02%
QTD
17.58%

Financial performance

How have Geron's revenue and profit performed over time
Revenue
$204.56M
Gross profit
$191.28M
Operating income
-$51.77M
Net income
-$67.61M
Gross margin
93.5%
Net margin
-33.1%
The operating margin rose by 46% year-on-year and by 4.2% since the previous quarter
GERN's net margin is up by 38% year-on-year and by 3.5% since the previous quarter
The operating income has grown by 33% YoY
The revenue has grown by 24% YoY and by 4.3% from the previous quarter

Price vs fundamentals

How does GERN's price correlate with its fundamentals

Growth

What is Geron's growth rate over time

Valuation

What is Geron stock price valuation
P/E
N/A
P/B
4.42
P/S
4.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.64
Geron's EPS has increased by 15% YoY
The P/B is 23% above the last 4 quarters average of 3.8 but 10% below the 5-year quarterly average of 5.2
Geron's equity has decreased by 16% YoY and by 4.6% from the previous quarter
The P/S is 100% below the 5-year quarterly average of 1281.5 but 9% above the last 4 quarters average of 4.8
The revenue has grown by 24% YoY and by 4.3% from the previous quarter

Efficiency

How efficient is Geron business performance
Geron's ROS has increased by 49% YoY
Geron's ROIC has increased by 43% YoY but it has decreased by 5% from the previous quarter
The ROA has grown by 25% YoY
GERN's ROE is up by 8% year-on-year but it is down by 4.6% since the previous quarter

Dividends

What is GERN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GERN.

Financial health

How did Geron financials performed over time
Geron's total assets is 73% higher than its total liabilities
The quick ratio has contracted by 24% YoY but it has grown by 4.1% from the previous quarter
GERN's current ratio is down by 12% year-on-year but it is up by 2.1% since the previous quarter
GERN's debt is 15% greater than its equity
GERN's debt to equity is up by 20% YoY and by 4.5% QoQ
Geron's equity has decreased by 16% YoY and by 4.6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.